{"id":"NCT03247556","sponsor":"Supernus Pharmaceuticals, Inc.","briefTitle":"Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD","officialTitle":"Evaluation of SPN-812 (Viloxazine Extended-release Capsule) 400 and 600 mg Efficacy and Safety in Adolescents With ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-20","primaryCompletion":"2019-02-14","completion":"2019-02-14","firstPosted":"2017-08-11","resultsPosted":"2021-07-02","lastUpdate":"2021-07-02"},"enrollment":297,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["ADHD"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":["PBO"]},{"type":"DRUG","name":"400mg SPN-812","otherNames":["SPN-812"]},{"type":"DRUG","name":"600mg SPN-812","otherNames":["SPN-812"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"400mg SPN-812","type":"EXPERIMENTAL"},{"label":"600mg SPN-812","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of high doses of SPN-812 in adolescents (12-17 years old) with ADHD","primaryOutcome":{"measure":"Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5)","timeFrame":"Baseline and Week 7 (End of Study)","effectByArm":[{"arm":"Placebo","deltaMin":-13.2,"sd":1.38},{"arm":"400mg SPN-812","deltaMin":-18.3,"sd":1.36},{"arm":"600mg SPN-812","deltaMin":-16.7,"sd":1.39}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0082"},{"comp":"OG000 vs OG002","p":"0.0712"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":14,"countries":["United States"]},"refs":{"pmids":["36847750","34523063","33971070","33600233"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":97},"commonTop":["Somnolence","Headache","Fatigue","Nausea","Decreased appetite"]}}